To solve the limitations of the current clinical use of TKI-resistance in CRC, we attempted to find microRNAs that can target EGFR/ErbB3 and inhibit the expression of these two genes to improve the efficacy of targeted therapy. This evidence concerns the gene ERBB3 and colorectal carcinoma.